新活素对冠心病介入患者血管内皮依赖性舒张功能、血浆NO含量影响

摘要/Abstract

摘要： 目的探讨新活素对冠心病介入患者血管内皮依赖性舒张功能、血浆NO含量的影响。方法选取2020年3月~2022年3月牡丹江医学院附属红旗医院收治的100例冠心病介入患者作为研究对象,按照随机数表法分为对照组和观察组,每组50例。对照组给予常规药物治疗（按照患者的临床表现及病情的特点给予患者制订合理的治疗方案,包括给予硝酸酯类药物、抗血小板药、抗凝药等）,研究组在常规基础上给予新活素治疗。观察两组临床疗效、生化指标变化情况、血管内皮依赖性舒张功能（FMD）、血浆一氧化氮（NO）含量以及不良反应发生率。结果研究组患者治疗的总有效率显著高于对照组,差异有统计学意义（P<0.05）。治疗前,两组患者超敏C反应蛋白（hs-CRP）、B型利钠肽（BNP）与白细胞介素 -6（IL-6）指标比较,差异无统计学意义（P>0.05）;治疗后,研究组各项指标明显低于对照组,差异有统计学意义（P<0.05）。治疗前,两组患者的FMD和血浆NO含量比较差异无统计学意义（P>0.05）;治疗后,两组患者的FMD和血浆NO含量均升高且研究组FMD和血浆NO含量均高于对照组,差异有统计学意义（P<0.05）。研究组患者的不良反应发生率低于对照组,差异有统计学意义（P<0.05）。结论新活素用于冠心病介入患者治疗能够很好地提升FMD,改善心功能,增加血浆NO的含量,疗效显著,且不良反应发生率低、安全可靠,为冠心病的治疗提供了新的思路和治疗手段。

关键词: 新活素, 冠心病, 血管内皮依赖性舒张功能, 血浆NO

Abstract: Objective To investigate the effects of lyophilized recombinant human brain natriuretic peptide on endothelium dependent vasodilation and plasma NO in patients with coronary artery disease (CAD) after percutaneous coronary intervention. Methods From March 2020 to March 2022, 100 patients with coronary intervention who were admitted to the Hongqi Hospital affiliated to Mudanjiang Medical College were selected and divided into two groups (named study group and control group respectively) according to the random number table. The patients were treated with routine drugs (according to the clinical manifestations and characteristics of the disease, the patients were given a reasonable treatment plan, including nitrates, antiplatelet drugs, anticoagulants, etc.). The study group of 50 patients was treated with lyophilized recombinant human brain natriuretic peptide on a routine basis. The clinical efficacy, changes in biochemical indicators, flow mediated dilation (FMD) Plasma (nitric oxide, NO) and the incidence of adverse reactions. Results The total effective rate of patients in the study group was significantly higher than that in the control group (P<0.05). There was no significant difference in hs-CRP, BNP and IL-6 between the two groups before treatment (P>0.05), after treatment, the indexes in the study group were significantly lower than those in the control group (P<0.05). There was no significant difference between the two groups in the levels of FMD and plasma NO before treatment (P>0.05), and after treatment, the levels of FMD and plasma NO in the two groups were both increased (P<0.05), and the levels of the above indicators in the study group were higher than those in the control group (P<0.05). The incidence of adverse reaction in the study group was lower than that in the control group (P<0.05). Conclusion Lyophilized recombinant human brain natriuretic peptide can improve endothelium dependent vasodilation function, improve cardiac function, increase plasma NO content in patients with coronary heart disease after intervention. It has significant effect, and the incidence of adverse reactions is low. Furthermore, it is safe and reliable. It provides a new idea and treatment method for the treatment of coronary heart disease.

Key words: lyophilized recombinant human brain natriuretic peptide, coronary heart disease, endothelium-dependent vasodilation, plasma NO

中图分类号:

R543

谢骏, 符北京, 高凤敏. 新活素对冠心病介入患者血管内皮依赖性舒张功能、血浆NO含量影响[J]. 中华养生保健, 2022, 40(24): 8-11.

XIE Jun, FU Bei-jing, GAO Feng-min. Effect of Neovasin on Endothelium - Dependent Vasodilation and Plasma NO Level in Patients with Coronary Heart Disease undergoing Percutaneous Coronary Intervention[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(24): 8-11.

参考文献

[1] Zhou J, Chen L, Yang X, et al.Preliminary study of the relationship between promoter methylation of the ANGPTL2 gene and coronary heart disease[J]. J Clinical Laboratory Analysis,2019,33(3):e22702.
[2] 吴洁,马艳辉,连一闻,等.冠状动脉粥样硬化性心脏病合并心律失常老年患者行经鼻内镜巨大垂体瘤切除术麻醉管理1例[J].国际麻醉学与复苏杂志,2021,42(2):171-175
[3] Ta H T, Alsaied T, Steele J M, et al.Atrial Function and Its Role in the Non-invasive Evaluation of Diastolic Function in Congenital Heart Disease[J]. Pediatric Cardiology,2020,41(4): 342-348.
[4] 朱洪新,王皓,霍建凤,等.盐酸多巴酚丁胺或左西孟旦治疗急性心力衰竭的临床效果及对血清脑利钠肽、尿酸的影响观察[J].临床误诊误治,2020,11(9):24-28.
[5] 刘书文,李虹,张诗义,等.短期应用托伐普坦联合米力农治疗老年难治性心力衰竭的临床疗效及预后观察[J].中国循证心血管医学杂志,2020,12(6):723-727
[6] 王彬苏,张琼芳,叶澍承,等.新活素治疗慢性心力衰竭的临床疗效观察[J].中国慢性病预防与控制,2019,27(2):114-116.
[7] 朱建华. 《2016年欧洲心血管疾病预防的临床实践指南》解读[J].中国介入心脏病学杂志,2016,24(11):619-622.
[8] 刘欣,王晓芳,吴延佳,等.银杏叶提取物联合天麻素注射液对血管源性眩晕患者动脉血流速度、血管内皮功能及溶血磷脂酸、酸性磷脂水平的影响[J].疑难病杂志,2021,20(4):363-367.
[9] 李翔,郑文武.注射用益气复脉(冻干)联合米力农治疗急性心肌梗死合并心衰疗效及对患者血清IL-6、CRP水平的影响[J].药物评价研究,2021,44(11):2498-2504.
[10] 吴翔宇,黄觊,李志忠,等.不同冠状动脉血运重建方式对80岁及以上高龄冠心病患者长期心血管相关死亡率影响的比较[J].中国循证心血管医学杂志,2021,13(5):592-596.
[11] 王玉芳,魏婕.急性心肌梗死患者经皮冠状动脉介入术后早期应用重组人脑利钠肽的疗效[J].川北医学院学报,2021.36(4):521-523.
[12] 薛茫,胡桃红.新活素对急性心肌梗死后顽固性心力衰竭患者心功能的影响及临床疗效的观察[J].中国医药导报,2019,16(10):154-156,161.
[13] 杨雪. 新活素对难治性心衰患者血清超敏C反应蛋白及B型脑钠肽的影响分析[J].中国现代药物应用,2019,13(3):71-72.
[14] 王帆. 新活素联合小剂量速尿治疗急性心肌梗死合并心力衰竭的临床价值研究[J].中国医药指南,2019,17(24):95-95.
[15] 张诗锐,朱理,袁玉玲,等.新活素与硝普钠对急性失代偿心力衰竭患者cTnINT-proBNPhs-CRP水平的影响[J].河北医学,2020,26(9): 1429-1434.
[16] 马占青,韩琼.高血压患者血清过氧化物酶体增殖物激活受体γ和氧化型低密度脂蛋白水平与血管内皮功能的相关性[J].中华高血压杂志,2020,28(11):1063-1066.
[17] 陈应辉. 小剂量多巴胺联合重组人脑钠肽治疗急性前壁心肌梗死急诊经皮冠状动脉介入治疗术后合并心力衰竭患者的效果及对预后的影响[J].现代消化及介入诊疗,2019,0(A1):903.
[18] 张凤云,徐晤,王向东,等.新活素对急性心肌梗死后心力衰竭的疗效及安全性分析[J].医学研究杂志,2019,48(6):50-54.
[19] 张冰. 探讨新活素治疗急诊急性心肌梗死合并心力衰竭患者的临床疗效[J].中国现代药物应用,2019,13(21):113-114.